# Probiotic oral care Live-bacteria lozenges and dissolving tablets that seed the oral cavity with health-associated commensals — BLIS Technologies' Streptococcus salivarius K12/M18 (NZ), ProBiora Health's ProBiora3 (S. oralis/uberis/rattus), BioGaia's Lactobacillus reuteri Prodentis (licensed into Sunstar's GUM PerioBalance) — paired with Bristle's shotgun-sequencing oral-microbiome diagnostics. Source: https://en.bioecon.ru/technology/probiotic-oral-care/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: FDA DSHEA (US supplement) & EU food-supplement/novel-food (EFSA) & NMPA (CN) | OECD: Industrial biotechnology | Regulator: FDA (USA), EFSA (EU), NMPA (China)] Probiotic oral care seeds the mouth with live, health-associated commensal bacteria — typically delivered as a daily dissolving lozenge or chewable tablet — so that beneficial strains outcompete the species that drive caries, gingivitis and halitosis. The segment is built on named strains rather than wellness claims: BLIS Technologies' two Streptococcus salivarius strains K12 (a bacteriocin producer active against breath and upper- respiratory pathogens) and M18 (which limits the biofilm behind caries), ProBiora Health's patented 3-strain ProBiora3 blend (S. oralis, S. uberis, S. rattus), and BioGaia's Lactobacillus reuteri Prodentis — two patented strains (ATCC PTA 5289 and DSM 17938) backed by 30+ years of research and licensed into Sunstar's GUM PerioBalance. The evidence base is active: four new peer-reviewed studies on S. salivarius K12/M18 appeared in the first half of 2026. A diagnostics layer — Bristle's at-home shotgun-sequencing test — reads the oral microbiome to target intervention. The key directions of probiotic oral care are: 1. **Named-strain S. salivarius probiotics:** BLIS K12 (breath and upper respiratory, via bacteriocin production) and M18 (caries/biofilm control). 2. **Multi-strain competitive-exclusion blends:** ProBiora3 (3 oralis-group streptococci) and Hyperbiotics Pro-Dental, occupying adhesion niches to crowd out pathogens. 3. **L. reuteri gum-health lozenges:** BioGaia Prodentis (2 patented strains), licensed into Sunstar's GUM PerioBalance. 4. **Oral-microbiome diagnostics:** Bristle's shotgun DNA sequencing scores caries, gingivitis/periodontitis and halitosis risk to guide use. ### Sectoral value chain ``` [strain banking] ──> [fermentation] ──> [lyophilization] ──> [tableting] │ (stabilized live CFU) │ ▼ [daily regimen] <─── [retail / DTC] <─────┘ ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Strain isolation & banking** | isolate health-associated oral commensals | **In:** healthy-patient oral samples. **Out:** master bank vials. | | **Fermentation & biomass** | grow strains to target density in bioreactors | **In:** media, starter culture. **Out:** liquid cell concentrate. | | **Stabilization (lyophilization)** | freeze-dry cells into stable powder | **In:** cell concentrate, cryoprotectant. **Out:** live-CFU powder. | | **Formulation & tableting** | blend into lozenges or dissolving tablets | **In:** CFU powder, excipients, flavour. **Out:** finished SKU. | | **Clinical validation** | RCT and bacteriocin/biofilm assays | **In:** product, trial protocol. **Out:** efficacy evidence. | | **Retail / DTC delivery** | daily-regimen sale to consumers | **In:** packaged SKU. **Out:** consumer oral-health outcome. | Cross-cutting technologies of the sector: - **Bacteriocin-producing cocci (Bacteriocin-Producing Cocci):** S. salivarius K12 secretes lantibiotic-class bacteriocins that inhibit Streptococcus pyogenes and related pathogens. - **Competitive-exclusion strain blending (Competitive-Exclusion Blending):** combining oralis-group streptococci or L. reuteri pairs to occupy adhesion sites and deplete pathogen substrates. - **Oral-microbiome shotgun sequencing (Oral-Microbiome Sequencing):** metagenomic readout of the oral bacterial/fungal community for risk scoring. --- ## US The US is the largest single market and the home of the competitive-exclusion blend segment, with BLIS's K12/M18 strains widely distributed across US probiotic shelves. ### named-strain pioneers, multi-strain blends, oral-microbiome diagnostics - **BLIS Technologies (NZ, US-marketed):** the strain-science pioneer — Streptococcus salivarius K12 and M18, with four new peer-reviewed studies landed in the first half of 2026. - **ProBiora Health:** the patented 3-strain ProBiora3 blend (S. oralis, S. uberis, S. rattus) as a once-daily dissolving tablet for breath, teeth, gums and natural whitening. - **Hyperbiotics:** Pro-Dental chewable tablets using clinically studied strains to lessen plaque build-up across the mouth and digestive tract. - **Bristle:** an at-home oral-microbiome DNA (shotgun) sequencing test scoring caries, gingivitis/periodontitis and halitosis risk — the diagnostics layer. --- ## CN China's oral-probiotic segment is emerging but still brand-thin on named-strain science: the shelf is dominated by toothpastes carrying generic "probiotic" claims rather than dedicated named-strain lozenges, so the regional picture is qualitative rather than vendor-led. ### probiotic-toothpaste claims, emerging supplements, regulatory boundary - **NMPA health-food / cosmetics boundary:** oral probiotics are regulated as health-food or cosmetics depending on claim, with named-strain health-food approvals still scarce. - **Probiotic toothpaste incumbents:** established oral-care brands add generic lactobacillus/bifidobacterium claims to toothpaste, not dedicated dissolving-tablet regimens. - **Limited named-strain leaders:** no Chinese originator of a K12/M18- or Prodentis-equivalent named-strain product has scaled, so the category imports strain science. --- ## EU Europe anchors the Lactobacillus reuteri gum-health line, with BioGaia's Prodentis strains — developed over 30+ years of research — licensed into Sunstar's GUM PerioBalance. ### L. reuteri Prodentis, strain licensing, clinical trials - **BioGaia (Sweden):** Prodentis lozenges carrying two patented L. reuteri strains (ATCC PTA 5289 and DSM 17938), backed by 30+ years of probiotic research. - **Sunstar (Switzerland/Japan):** GUM PerioBalance lozenges built on L. reuteri Prodentis strains licensed from BioGaia, with a registered clinical trial (NCT07443410). - **EU food-supplement framing:** EFSA treats oral probiotics as food supplements (or novel food for new strains), distinct from the US DSHEA supplement track. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **BLIS Technologies** | 🇳🇿 New Zealand | *S. salivarius K12/M18 oral probiotics* | bacteriocin-producing cocci, breath + caries strains, 4 studies H1 2026 | Commercial | | **ProBiora Health** | 🇺🇸 USA | *ProBiora3 dissolving tablets* | S. oralis/uberis/rattus 3-strain blend, 1 tablet/day | Commercial | | **Bristle** | 🇺🇸 USA | *Oral microbiome test* | shotgun DNA sequencing, caries/gingivitis/halitosis scoring | Commercial | | **BioGaia** | 🇸🇪 Sweden | *Prodentis lozenges* | L. reuteri ATCC PTA 5289 + DSM 17938, 30+ yrs research | Commercial | | **Hyperbiotics** | 🇺🇸 USA | *Pro-Dental chewable tablets* | clinically studied strain blend, plaque reduction | Commercial | | **Sunstar** | 🇨🇭 Switzerland | *GUM PerioBalance lozenges* | L. reuteri Prodentis (BioGaia-licensed), trial NCT07443410 | Commercial | --- ## Tech stack and innovations The stack is built on three microbiological platforms: bacteriocin-producing oral commensals, multi-strain competitive-exclusion blends, and metagenomic readout of the oral cavity. 1. **Bacteriocin-producing S. salivarius (Bacteriocin-Producing S. salivarius):** - K12 secretes lantibiotic-class bacteriocins that inhibit Streptococcus pyogenes and other upper-respiratory pathogens; M18 limits caries-associated biofilm. - case: BLIS Technologies' two-strain platform, with four new peer-reviewed studies in H1 2026. 2. **Competitive-exclusion blends (Competitive-Exclusion Blends):** - oralis-group streptococci and paired L. reuteri occupy adhesion niches and deplete pathogen substrates rather than killing them. - case: ProBiora3's 3-strain blend and BioGaia's 2-strain L. reuteri Prodentis (licensed to Sunstar GUM PerioBalance). 3. **Oral-microbiome shotgun sequencing (Oral-Microbiome Sequencing):** - metagenomic sequencing of the oral bacterial and fungal community quantifies caries, gingivitis and halitosis risk to guide probiotic use. - case: Bristle's at-home saliva test with DNA-based risk scoring. --- ## Value chains and production pipelines ### Industrial pipeline of a named-strain oral probiotic lozenge (FDA DSHEA / EU food-supplement) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Strain isolation │ ───> │ 2. Fermentation │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Tableting │ <─── │ 3. Lyophilization │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Clinical validation │ ───> │ 6. Retail / DTC regimen │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Strain isolation Health-associated commensals — S. salivarius K12/M18 or L. reuteri ATCC PTA 5289/DSM 17938 — are isolated from the oral cavity of healthy donors and master-banked. #### Stage 2: Fermentation The seed strain is grown to target cell density in a controlled bioreactor on a compatible growth medium, yielding liquid cell concentrate. #### Stage 3: Lyophilization The concentrate is freeze-dried with a cryoprotectant into a stable live-CFU powder that holds viability through shelf storage. #### Stage 4: Tableting The CFU powder is blended with excipients and mint flavour and pressed into a dissolving lozenge or chewable tablet, the format that maximizes oral-cavity residence time. #### Stage 5: Clinical validation The finished SKU is tested in a randomized trial and in bacteriocin/biofilm assays — e.g. Sunstar's GUM PerioBalance is the subject of registered trial NCT07443410. #### Stage 6: Retail / DTC regimen The product reaches the consumer as a once-daily dissolving tablet (ProBiora, BioGaia Prodentis) or chewable (Hyperbiotics Pro-Dental), supported by Bristle's sequencing test for targeted use.